Li, Yi-HengYi-HengLiTseng, Wei-KungWei-KungTsengYin, Wei-HsianWei-HsianYinFANG-JU LINYEN-WEN WUHsieh, I-ChangI-ChangHsiehLin, Tsung-HsienTsung-HsienLinSheu, Wayne Huey-HerngWayne Huey-HerngSheuYeh, Hung-IHung-IYehChen, Jaw-WenJaw-WenChenCHAU-CHUNG WUTaiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry Investigators2021-03-112021-03-1120202045-2322https://scholars.lib.ntu.edu.tw/handle/123456789/551597In patients with atherosclerotic cardiovascular disease (ASCVD) under statin treatment, the influence of on-treatment level of high-density lipoprotein cholesterol (HDL-C) on cardiovascular (CV) events is controversial. Statin-treated patients were selected from the Taiwanese Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) Registry, a multicenter, observational study of adult patients with ASCVD in Taiwan. Low HDL-C was defined as < 40 mg/dL for men and < 50 mg/dL for women. The primary outcome was a composite CV events including CV death, myocardial infarction (MI), stroke or cardiac arrest with resuscitation. A total of 3731 patients (mean age 65.6 years, 75.6% men) were included. Patients with on-treatment low HDL-C (44%, mean HDL-C 34.9 ± 6.8 mg/dL) were younger and with more diabetes and higher body weight. The mean follow-up time was 2.7 years. We used restricted cubic spline curves to examine the potential non-linear association between HDL-C and adverse outcomes. Decreased HDL-C levels were associated with a significantly increased risk of CV events in women (< 49 mg/dL in women) but not in men (< 42 mg/dL in men). However, the protective effect of elevated HDL-C levels was more prominent in men than in women. In ASCVD patients with statin therapy, low on-treatment HDL-C was common in Taiwan and associated with an increased risk of CV events in women. Higher HDL-C levels provided more protective effect in men than in women.HDL CHOLESTEROL; LDL CHOLESTEROL; RESIDUAL RISK; THERAPY; METAANALYSIS; MANAGEMENT; EFFICACY; SAFETY[SDGs]SDG3high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; aged; blood; cerebrovascular accident; clinical trial; coronary artery disease; female; follow up; heart infarction; human; male; middle aged; multicenter study; prognosis; prospective study; register; risk factor; Aged; Cholesterol, HDL; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Registries; Risk Factors; Strokejournal article10.1038/s41598-020-78828-8333185902-s2.0-85097566003WOS:000600104900002https://api.elsevier.com/content/abstract/scopus_id/85097566003https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097566003&doi=10.1038%2fs41598-020-78828-8&partnerID=40&md5=70b8927710a048c9deeab49d65215d03